Pharmacotherapeutic Strategies to Prevent Progression to ESKD and Reduce Cardiovascular Risk
By:
Ayodele Odutayo University Health Network, Toronto General Hospital Research Institute and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

Search for other papers by Ayodele Odutayo in
Current site
Google Scholar
PubMed Close
and
David Cherney University Health Network, Toronto General Hospital Research Institute, University of Toronto, Toronto, Canada

Search for other papers by David Cherney in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 23: Issue 4
Published Online:
Oct 2024
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2024 by the American Society of Nephrology 2024
Page Count:
16
Article Category:
Research Article
Print Publication Date:
01 Oct 2024
Published Online:
Oct 2024
  • 1.

    GBD Chronic Kidney Disease Collaboration: Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 395: 709–733, 2020 10.1016/S0140-6736(20)30045-3 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al.: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597, 2014 10.1161/CIRCULATIONAHA.113.005081 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Wada Y, Kidokoro K, Kondo M, Tokuyama A, Kadoya H, Nagasu H, et al.: Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging. Kidney Int 106: 408–418, 2024 10.1016/j.kint.2024.05.006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Yau K, Cherney DZI, van Raalte DH, Wever BE: Kidney protective mechanisms of SGLT2 inhibitors: Evidence for a hemodynamic effect. Kidney Int 105: 1168–1172, 2024 10.1016/j.kint.2024.03.019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    van Bommel EJM, Lytvyn Y, Perkins BA, Soleymanlou N, Fagan NM, Koitka-Weber A, et al.: Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. Kidney Int 97: 631–635, 2020 10.1016/j.kint.2019.12.021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Frederich R, VERTIS CV Investigators, et al.: Initial eGFR changes with ertugliflozin and associations with clinical parameters: Analyses from the VERTIS CV trial. Am J Nephrol 53: 516–525, 2022 10.1159/000524889 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Heerspink HJL, Cherney DZI: Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol 16: 1278–1280, 2021 10.2215/CJN.02480221 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, et al.: Characterization and implications of the initial estimated glomerular filtration rate “dip” upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 99: 750–762, 2021 10.1016/j.kint.2020.10.031 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, EMPA-KIDNEY Collaborative Group, et al.: Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD. J Am Soc Nephrol 35: 202–215, 2024 10.1681/ASN.0000000000000271 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, et al.: Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab 24: 1578–1587, 2022 10.1111/dom.14729 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Cherney DZ, Kanbay M, Lovshin JA: Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant 35[Suppl 1]: i3–i12, 2020 10.1093/ndt/gfz230 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, DIAMOND investigators, et al.: Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 8: 582–593, 2020 10.1016/S2213-8587(20)30162-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, CREDENCE Trial Investigators, et al.: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019 10.1056/NEJMoa1811744 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, DAPA-CKD Trial Committees and Investigators, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–1446, 2020 10.1056/NEJMoa2024816 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, The EMPA-KIDNEY Collaborative Group, et al.: Empagliflozin in patients with chronic kidney disease. N Engl J Med 388: 117–127, 2023 10.1056/NEJMoa2204233 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, SCORED Investigators, et al.: Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384: 129–139, 2021 10.1056/NEJMoa2030186 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Sridhar VS, Bhatt DL, Odutayo A, Szarek M, Davies MJ, Banks P, et al.: Sotagliflozin and kidney outcomes, kidney function, and albuminuria in type 2 diabetes and CKD: A secondary analysis of the SCORED trial. Clin J Am Soc Nephrol 19: 557–564, 2024 10.2215/CJN.0000000000000414 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Nuffield Department of Population Health Renal Studies Group: SGLT2 inhibitor meta-analysis cardio-renal trialists’ consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet 400: 1788–1801, 2022 10.1016/S0140-6736(22)02074-8 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, DAPA-CKD Trial Committees and Investigators, et al.: A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int 101: 174–184, 2022 10.1016/j.kint.2021.09.005 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al.: Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials. Circulation 145: 1460–1470, 2022 10.1161/CIRCULATIONAHA.121.057736 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105: S117–S314, 2024 10.1016/j.kint.2023.10.018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131–2157, 2007 10.1053/j.gastro.2007.03.054 PubMed

  • 23.

    Cherney DZI, Udell JA, Drucker DJ: Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med 2: 1203–1230, 2021 10.1016/j.medj.2021.10.004 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Yau K, Odutayo A, Dash S, Cherney DZI: Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection. Can J Cardiol 39: 1816–1838, 2023 10.1016/j.cjca.2023.07.007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, Tuttle K, Vrhnjak B, et al.: Hemoglobin A1c reduction with the GLP-1 receptor agonist semaglutide is independent of baseline eGFR: Post hoc analysis of the SUSTAIN and PIONEER programs. Kidney Int Rep 7: 2345–2355, 2022 10.1016/j.ekir.2022.07.167 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Cherney DZ, Tuttle KR: Liraglutide for the treatment of type 2 diabetes and safety in diabetic kidney disease: Liraglutide and diabetic kidney disease. Clin J Am Soc Nephrol 15: 444–446, 2020 10.2215/CJN.01260120 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, et al.: Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int 103: 772–781, 2023 10.1016/j.kint.2022.12.028 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, et al.: Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: Pooled analysis of SUSTAIN 6 and LEADER. Circulation 145: 575–585, 2022 10.1161/CIRCULATIONAHA.121.055459 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, REWIND Investigators, et al.: Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394: 131–138, 2019 10.1016/S0140-6736(19)31150-X PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, FLOW Trial Committees and Investigators, et al.: Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391: 109–121, 2024 10.1056/NEJMoa2403347 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al.: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 30: 2058–2066, 2024 10.1038/s41591-024-03015-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al.: Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: Post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10: 774–785, 2022 10.1016/S2213-8587(22)00243-1 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al.: Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42: 152–161, 2021 10.1093/eurheartj/ehaa736 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Albakr RB, Sridhar VS, Cherney DZI: Novel therapies in diabetic kidney disease and risk of hyperkalemia: A review of the evidence from clinical trials. Am J Kidney Dis 82: 737–742, 2023 10.1053/j.ajkd.2023.04.015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, FIDELIO-DKD Investigators, et al.: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383: 2219–2229, 2020 10.1056/NEJMoa2025845 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, FIGARO-DKD Investigators, et al.: Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385: 2252–2263, 2021 10.1056/NEJMoa2110956 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, FIDELIO-DKD and FIGARO-DKD Investigators, et al.: A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int 103: 196–206, 2023 10.1016/j.kint.2022.08.040 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Oberprieler NG, Kovesdy CP, Layton JB, Thapa B, Curhan G, Farjat AE, et al.: Clinical outcomes in US patients initiating finerenone – A report from the FOUNTAIN platform. Nephrology Dialysis Transplantation 39[Suppl 1]: gfae069-1416–2022, 2024 10.1093/ndt/gfae069.1416

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, FIND-CKD investigators, et al.: Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial [published online ahead of print Jun 11, 2024]. Nephrol Dial Transplant doi:10.1093/ndt/gfae132 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, et al.: Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract 204: 110908, 2023 10.1016/j.diabres.2023.110908 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, ASi in CKD group, et al.: Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: A randomised, controlled, phase 2 trial. Lancet 403: 379–390, 2024 10.1016/S0140-6736(23)02408-X PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Kohan DE, Barton M: Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 86: 896–904, 2014 10.1038/ki.2014.143 PubMed

  • 43.

    Mann JFE, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, ASCEND Study Group, et al.: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527–535, 2010 10.1681/ASN.2009060593 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Heerspink HJL, Parving H-H, Andress DL, Bakris G, Correa-Rotter R, Hou F-F, SONAR Committees and Investigators, et al.: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 393: 1937–1947, 2019 10.1016/S0140-6736(19)30772-X PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, et al.: Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): A multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 402: 2004–2017, 2023 10.1016/S0140-6736(23)02230-4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, DUPRO steering committee and PROTECT Investigators, et al.: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402: 2077–2090, 2023 10.1016/S0140-6736(23)02302-4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae D-W, DUPRO Steering Committee and DUPLEX Investigators, et al.: Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N Engl J Med 389: 2436–2445, 2023 10.1056/NEJMoa2308550 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Alberta Kidney Disease Network, et al.: Cause of death in patients with reduced kidney function. J Am Soc Nephrol 26: 2504–2511, 2015 10.1681/ASN.2014070714 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Mark PB, Carrero JJ, Matsushita K, Sang Y, Ballew SH, Grams ME, et al.: Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: A CKD Prognosis Consortium study. Eur Heart J 44: 1157–1166, 2023 10.1093/eurheartj/ehac825 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015 10.1056/NEJMoa1504720 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, CANVAS Program Collaborative Group, et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657, 2017 10.1056/NEJMoa1611925 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, DECLARE–TIMI 58 Investigators, et al.: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347–357, 2018 10.1056/NEJMoa1812389 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al.: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393: 31–39, 2018 10.1016/S0140-6736(18)32590-X PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Patel SM, Kang YM, Im KAH, Neuen BL, Anker SD, Bhatt DL, et al.: Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: A SMART-C collaborative meta-analysis. Circulation 149: 1789–1801, 2024 10.1161/CIRCULATIONAHA.124.069568 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Arnett DK, Blumenthal RS, Albert MA, Buroker A, Goldberger ZD, Hahn EJ, et al.: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140: e596–e646, 2019 10.1161/CIR.0000000000000678 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Peer Review Committee Members, et al.: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 148: e9–e119, 2023 10.1161/CIR.0000000000001168 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, DAPA-HF Trial Committees and Investigators, et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381: 1995–2008, 2019 10.1056/NEJMoa1911303 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, EMPEROR-Reduced Trial Investigators, et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383: 1413–1424, 2020 10.1056/NEJMoa2022190 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, EMPEROR-Preserved Trial Investigators, et al.: Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385: 1451–1461, 2021 10.1056/NEJMoa2107038 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, DELIVER Trial Committees and Investigators, et al.: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387: 1089–1098, 2022 10.1056/NEJMoa2206286 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, SOLOIST-WHF Trial Investigators, et al.: Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384: 117–128, 2021 10.1056/NEJMoa2030183 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, et al.: Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol 6: 499–507, 2021 10.1001/jamacardio.2020.7585 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, et al.: Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol 7: 1259–1263, 2022 10.1001/jamacardio.2022.3750 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145: e895–e1032, 2022 10.1161/CIR.0000000000001063 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al.: Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid 3: EVIDoa2300286, 2023 10.1056/EVIDoa2300286 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al.: Empagliflozin after acute myocardial infarction. N Engl J Med 390: 1455–1466, 2024 10.1056/NEJMoa2314051 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Bain SC, et al.: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375: 1834–1844, 2016 10.1056/NEJMoa1607141 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, PIONEER 6 Investigators, et al.: Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381: 841–851, 2019 10.1056/NEJMoa1901118 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, et al.: Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab 25: 1932–1941, 2023 10.1111/dom.15058 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, SELECT Trial Investigators, et al.: Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389: 2221–2232, 2023 10.1056/NEJMoa2307563 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, LEADER Trial Investigators, et al.: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375: 311–322, 2016 10.1056/NEJMoa1603827 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, REWIND Investigators, et al.: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 394: 121–130, 2019 10.1016/S0140-6736(19)31149-3 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, FIDELIO-DKD and FIGARO-DKD investigators, et al.: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 43: 474–484, 2022 10.1093/eurheartj/ehab777 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al.: Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45: 3075–3090, 2022 10.2337/dci22-0027 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, SHARP Investigators, et al.: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377: 2181–2192, 2011 10.1016/S0140-6736(11)60739-3 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Herrington W, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu M, Cholesterol Treatment Trialists’ (CTT) Collaboration, et al.: Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: A meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4: 829–839, 2016 10.1016/S2213-8587(16)30156-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Wanner C, Tonelli M, the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members: KDIGO clinical practice guideline for lipid management in CKD: Summary of recommendation statements and clinical approach to the patient. Kidney Int 85: 1303–1309, 2014 10.1038/ki.2014.31 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al.: Estimated lifetime cardiovascular, kidney and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 149: 450–462, 2023 10.1161/CIRCULATIONAHA.123.067584 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 3601 3601 367
Full Text Views 514 514 75
PDF Downloads 700 700 101